Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.43 |
| ▸ | MYLK4 | Q86YV6 | 1/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.43 |
| ▸ | MAP3K12 | Q12852 | 13/20 | 0.37 |
| ▸ | EGFR | P00533 | 2/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | CDK4 | P11802 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4286551 | 0.89 | PAK1 (0.39) | EGFRBTK | |
| SCHEMBL4279026 | 0.87 | STK17A (0.42) | STK17AMYLK4CLK4MAP3K12EGFR | |
| SCHEMBL4279933 | 0.84 | STK17A (0.43) | STK17AMYLK4CLK4MAP3K12EGFR | |
| SCHEMBL4279022 | 0.84 | STK17A (0.43) | STK17AMYLK4CLK4MAP3K12EGFR | |
| SCHEMBL4281898 | 0.82 | STK17A (0.45) | STK17AMYLK4CLK4MAP3K12EGFR | |
| SCHEMBL4280962 | 0.82 | STK17A (0.45) | STK17AMYLK4CLK4MAP3K12EGFR | |
| SCHEMBL4284312 | 0.81 | STK17A (0.48) | STK17AMYLK4CLK4SYK | |
| SCHEMBL4281316 | 0.81 | STK17A (0.48) | STK17AMYLK4CLK4SYK | |
| SCHEMBL4276690 | 0.80 | STK17A (0.48) | STK17AMYLK4CLK4MAP3K12SYK | |
| SCHEMBL4286106 | 0.80 | STK17A (0.48) | STK17AMYLK4CLK4MAP3K12SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309566-B2 | Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases | RIGEL PHARMACEUTICALS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20090258864-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | RIGEL PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258864-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | JAK2, JAK1, JAK3 | STK17A 229/4885MYLK4 1872/4885CLK4 689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.